Study guide

8.3 Theft, Significant Loss (DEA Form 106) & Disposal/Destruction (DEA Form 41)

NABP MPJE Multistate Pharmacy Jurisprudence Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pharmacist Licensure & Reciprocity

1.1 Initial Licensure Requirements & Examinations 1.2 License Renewal, Continuing Education (CE) & Status 1.3 Reciprocity, License Transfer & Multistate Licensure 1.4 Disciplinary Actions, Board Hearings, Sanctions & Reinstatement

2 Chapter 2: Pharmacy Personnel Roles & Supervision Ratios

2.1 Pharmacy Interns: Scope of Practice, Supervision & Preceptor Rules 2.2 Pharmacy Technicians: Registration, Certification & Permitted Duties 2.3 Technician-to-Pharmacist Ratios & Delegated Tasks 2.4 Non-Pharmacist Personnel & Automated Dispensing Technology Roles

3 Chapter 3: Prescriptive Authority & Practitioner Categories

3.1 Physicians, Dentists, Veterinarians & Podiatrists: Prescribing Scope 3.2 Mid-Level Practitioners: APNs, PAs, Optometrists & Independent Authority 3.3 Out-of-State, Foreign & Deceased Practitioner Prescriptions 3.4 Self-Prescribing & Prescribing for Family Members

4 Chapter 4: Patient Counseling & Drug Utilization Review (OBRA '90)

4.1 OBRA '90 Mandates & Prospective Drug Utilization Review (DUR) 4.2 Patient Counseling Requirements, Offer-to-Counsel & Documentation 4.3 Patient Profile Requirements & Retrospective DUR

5 Chapter 5: Advanced Pharmacist Practice & Collaborative Agreements

5.1 Collaborative Practice Agreements (CPAs) & Protocol-Based Care 5.2 Pharmacist Immunization Authority & Vaccine Administration Protocols 5.3 Medication Therapy Management (MTM) & Point-of-Care Testing (POCT) 5.4 Hormonal Contraceptive, Naloxone & Post-Exposure Prophylaxis (PEP/PrEP) Prescribing

6 Chapter 6: Federal Controlled Substances Act (CSA) & Scheduling

6.1 Controlled Substance Schedules (CI through CV) & Classification Criteria 6.2 DEA Registration: Types, Forms (224, 225, 363) & Renewal Cycles 6.3 Scheduled Listed Chemical Products (SLCPs) & Combat Methamphetamine Epidemic Act (CMEA)

7 Chapter 7: Controlled Substance Prescriptions & Legitimate Purpose

7.1 Corresponding Responsibility & Red Flags for Improper Prescribing 7.2 Required Components of Controlled Substance Prescriptions 7.3 Electronic Prescriptions for Controlled Substances (EPCS) & Security Requirements 7.4 Emergency Schedule II Prescriptions & Partial Filling Rules (CARA Act)

8 Chapter 8: Controlled Substance Ordering, Inventory & Recordkeeping

8.1 Ordering Schedule II Substances: CSOS & DEA Form 222 Execution 8.2 Controlled Substance Inventory Requirements (Initial, Biennial, Count Exactness) 8.3 Theft, Significant Loss (DEA Form 106) & Disposal/Destruction (DEA Form 41) 8.4 Prescription Transfers & Prescription Drug Monitoring Programs (PDMPs)

9 Chapter 9: Federal Pure Food, Drug & Cosmetic Act (FD&C Act) & Drug Safety

9.1 Adulteration vs. Misbranding: Statutory Definitions & Legal Violations 9.2 Prescription Labeling Requirements, Expiration Dates & Side Effect Statements 9.3 Poison Prevention Packaging Act (PPPA) & Child-Resistant Container Exemptions 9.4 Drug Recalls (Class I, II, III) & Market Withdrawals 9.5 Drug Product Selection, Generic Substitution & DAW Codes 9.6 Returning & Reusing Dispensed Drugs: Restocking, Redispensing & Repository Programs

10 Chapter 10: Drug Supply Chain Security Act (DSCSA) & Commercial Distribution

10.1 DSCSA Track-and-Trace Requirements: Transaction Information & Statements 10.2 Suspect & Illegitimate Product Verification, Quarantine & Notification 10.3 Prescription Drug Marketing Act (PDMA): Samples, Reimportation & Wholesale Distribution

11 Chapter 11: Compounding Standards: USP <795>, <797> & <800>

11.1 Section 503A vs. 503B Compounding Facilities (DQSA Architecture) 11.2 Non-Sterile Compounding (USP <795>) & Beyond-Use Dating (BUD) 11.3 Sterile Compounding (USP <797>): Air Quality, Cleanrooms & BUD 11.4 Hazardous Drug Handling (USP <800>): Engineering Controls & Personal Protective Equipment

12 Chapter 12: Pharmacy Operational Security, Records & Telepharmacy

12.1 Physical Pharmacy Security, Alarm Systems & Keyholder Rules 12.2 Mandatory Pharmacy Records Retention & Audit Inspection Readiness 12.3 Central Fill, Automated Dispensing Systems (ADS) & Telepharmacy Operations 12.4 HIPAA Privacy Rule, Patient Records & Breach Notification Protocols

8.3 Theft, Significant Loss (DEA Form 106) & Disposal/Destruction (DEA Form 41)

Key Takeaways Explain This Topic AI

Theft or significant loss of controlled substances must be reported in writing to the DEA within 1 business day of discovery, followed by electronic Form 106 submission.

Supplier is responsible for reporting in-transit losses before delivery receipt; purchaser is responsible after signing for delivery.

Controlled substance disposal must be conducted via a DEA-registered Reverse Distributor or approved destruction process.

Transferring Schedule II drugs to a reverse distributor requires the reverse distributor to issue DEA Form 222 to the pharmacy.

DEA Form 41 is executed by the reverse distributor (or registrant) to certify final non-retrievable drug destruction.

Last updated: July 2026

8.3 Theft, Significant Loss (DEA Form 106) & Disposal/Destruction (DEA Form 41)

Controlled substances present significant diversion risks. The DEA enforces strict protocols for reporting inventory shortages resulting from theft or significant loss (21 CFR § 1301.76) and for disposing of expired, damaged, or unwanted controlled stock (21 CFR Part 1317). Pharmacists must master the distinct roles of DEA Form 106 and DEA Form 41 .

Reporting Theft or Significant Loss: The 1 Business Day Rule

When a pharmacy discovers a theft or significant loss of controlled substances, federal law imposes an immediate notification obligation.

Mandatory Timeline:

Initial Written Notification : The pharmacy must notify the local DEA Field Division in writing within ONE BUSINESS DAY of discovery of the theft or significant loss.

Written notification may be transmitted via email, fax, or official DEA online portal.

Local law enforcement and the state board of pharmacy should also be notified per state requirements.

Formal Report (DEA Form 106) : After conducting an internal investigation to gather details, the pharmacy submits DEA Form 106 electronically via the DEA secure application.

If an initial notification was submitted but investigation reveals that no theft or loss actually occurred , or that the loss was not significant , the pharmacy is not required to submit Form 106. However, the pharmacy must notify the DEA in writing explaining why Form 106 was not filed.

Determining "Significant Loss"

The DEA does not establish a fixed numerical quantity to define a "significant loss." Instead, the registrant must evaluate the following legal criteria:

Specific drug quantity lost : (e.g., 5 tablets of hydrocodone vs. 1,000 tablets).

Specific drug schedule and abuse potential : Loss of Schedule II opioids (fentanyl, oxycodone) carries higher significance than Schedule V antitussives.

Likelihood of diversion : Whether the missing drugs are likely targeted for illicit street distribution.

Patterns of loss : Repeated small losses occurring over a specific time frame (e.g., recurring inventory variances tied to specific shifts or personnel).

Individual responsibility : Whether the loss is bound to specific individuals or unknown access points.

In-Transit Loss Responsibilities

When controlled substances are stolen or lost during transport between a wholesaler/supplier and a pharmacy, legal responsibility depends on custody transfer :

  • Scenario Responsible Party Required Action
  • Loss before purchaser signs delivery receipt Supplier (Wholesaler) Supplier submits DEA Form 106
  • Loss after purchaser signs delivery receipt Purchaser (Pharmacy) Purchaser submits DEA Form 106

Central Fill Shipment Loss Central Fill Pharmacy or Retail Pharmacy Depends on contract carrier arrangement and custody transfer point

Disposal and Destruction Standards

Under the Secure and Responsible Drug Disposal Act of 2010 and 21 CFR Part 1317, pharmacies cannot destroy controlled substances by flushing them down drains or discarding them in standard trash. Destruction must render the drug non-retrievable (permanently altering the substance's physical or chemical condition so it cannot be recovered or reconstituted).

Primary Disposal Route: DEA-Registered Reverse Distributor

The standard and most common method for pharmacy controlled substance disposal is transferring stock to a DEA-Registered Reverse Distributor .

Transfer Protocols:

Schedule II Transfer : The reverse distributor acts as the purchaser and must issue a DEA Form 222 (or CSOS order) to the pharmacy. The pharmacy acts as the supplier and fills the Form 222 by shipping the expired/damaged CII items.

Schedule III–V Transfer : Documented via an invoice or manifest recording drug name, dosage form, strength, quantity, and transfer date.

Form 41 Execution : The Reverse Distributor —not the pharmacy—is responsible for submitting DEA Form 41 to the DEA once the controlled substances have been physically destroyed.

Secondary Disposal Route: Registrant On-Site Destruction

If a pharmacy wishes to destroy controlled substances on-site:

The pharmacy must request prior authorization from the local DEA Special Agent in Charge using DEA Form 41 .

Destruction must be witnessed by two authorized employees (at least one licensed pharmacist).

Form 41 must document the drug details, method of destruction, and signatures of both witnesses.

Accidental Breakage and Spillage

Accidental breakage or spillage of controlled substances (e.g., dropping a liquid methadone bottle or crushing tablets) is NOT considered a theft or significant loss :

Do NOT file DEA Form 106 for accidental breakage/spillage unless drugs were stolen.

Recoverable Waste : If spilled drug residue is recoverable, it must be disposed of via a reverse distributor and recorded on DEA Form 41.

Unrecoverable Waste : If liquid is absorbed into carpet or washed away, the event must be documented in pharmacy records signed by two witnessing employees explaining the incident.

Loading diagram... Controlled Substance Discrepancy & Disposal Action Matrix